
Bioventus (BVS) Stock Forecast & Price Target
Bioventus (BVS) Analyst Ratings
Bulls say
Bioventus Inc reported a quarterly revenue of $55.5 million from its surgical solutions segment, reflecting a 3.4% increase and a robust 10.3% growth after excluding the impact of divestitures, driven by effective commercial strategies and sales execution in its Exogen system. The pain treatments segment performed exceptionally well with $79.7 million in revenue, supported by anticipated future growth investments aimed at enhancing performance in peripheral nerve stimulation, platelet-rich plasma, and other areas. Management's guidance indicates a strong outlook for both segments, projecting low double-digit growth for surgical solutions in 2026 and significant adjusted EBITDA margin improvements anticipated between 2025 and 2030.
Bears say
Bioventus is expected to invest heavily in key growth areas during 2026 and 2027, which may lead to flat or slightly declining adjusted EBITDA margins compared to 2025. The company reported a significant decline of 26.0% in restorative therapies revenue, coupled with an overall 8.6% decline in international revenue, raising concerns about its growth trajectory. Additionally, the gross margin for the quarter was below expectations at 68.9%, further highlighting potential operational inefficiencies.
This aggregate rating is based on analysts' research of Bioventus and is not a guaranteed prediction by Public.com or investment advice.
Bioventus (BVS) Analyst Forecast & Price Prediction
Start investing in Bioventus (BVS)
Order type
Buy in
Order amount
Est. shares
0 shares